These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. T wave peak-to-end interval and QT dispersion in acquired long QT syndrome: a new index for arrhythmogenicity. Yamaguchi M; Shimizu M; Ino H; Terai H; Uchiyama K; Oe K; Mabuchi T; Konno T; Kaneda T; Mabuchi H Clin Sci (Lond); 2003 Dec; 105(6):671-6. PubMed ID: 12857349 [TBL] [Abstract][Full Text] [Related]
23. Drug-induced QT prolongation and torsades de pointes: evaluation of a QT nomogram. Chan A; Isbister GK; Kirkpatrick CM; Dufful SB QJM; 2007 Oct; 100(10):609-15. PubMed ID: 17881416 [TBL] [Abstract][Full Text] [Related]
24. QT interval prolongation and the risk of torsades de pointes: essentials for clinicians. Trinkley KE; Page RL; Lien H; Yamanouye K; Tisdale JE Curr Med Res Opin; 2013 Dec; 29(12):1719-26. PubMed ID: 24020938 [TBL] [Abstract][Full Text] [Related]
25. Mexiletine effectively prevented refractory Torsades de Pointes and ventricular fibrillation in a patient with congenital type 2 long QT syndrome. Nakashima R; Takase S; Kai K; Sakamoto K; Tsutsui H J Cardiovasc Electrophysiol; 2022 Jul; 33(7):1592-1595. PubMed ID: 35488741 [TBL] [Abstract][Full Text] [Related]
26. Increased ventricular ectopy precedes Torsades de Pointes in patients with prolonged QT. Marill KA; Lopez S; Hark D; Spahr J; Kapadia N; Liu SW J Electrocardiol; 2023; 80():17-23. PubMed ID: 37105125 [TBL] [Abstract][Full Text] [Related]
27. An explainable algorithm for detecting drug-induced QT-prolongation at risk of torsades de pointes (TdP) regardless of heart rate and T-wave morphology. Alahmadi A; Davies A; Royle J; Goodwin L; Cresswell K; Arain Z; Vigo M; Jay C Comput Biol Med; 2021 Apr; 131():104281. PubMed ID: 33636421 [TBL] [Abstract][Full Text] [Related]
28. Combined pharmacological block of I(Kr) and I(Ks) increases short-term QT interval variability and provokes torsades de pointes. Lengyel C; Varró A; Tábori K; Papp JG; Baczkó I Br J Pharmacol; 2007 Aug; 151(7):941-51. PubMed ID: 17533421 [TBL] [Abstract][Full Text] [Related]
29. Observations on the onset of torsade de pointes arrhythmias in the acquired long QT syndrome. Vos MA; Gorenek B; Verduyn SC; van der Hulst FF; Leunissen JD; Dohmen L; Wellens HJ Cardiovasc Res; 2000 Dec; 48(3):421-9. PubMed ID: 11090837 [TBL] [Abstract][Full Text] [Related]
30. Beat-by-beat QT interval variability, but not QT prolongation per se, predicts drug-induced torsades de pointes in the anaesthetised methoxamine-sensitized rabbit. Jacobson I; Carlsson L; Duker G J Pharmacol Toxicol Methods; 2011; 63(1):40-6. PubMed ID: 20451633 [TBL] [Abstract][Full Text] [Related]
31. Citalopram induced torsade de pointes, a rare life threatening side effect. Kanjanauthai S; Kanluen T; Chareonthaitawee P Int J Cardiol; 2008 Dec; 131(1):e33-4. PubMed ID: 17919753 [TBL] [Abstract][Full Text] [Related]
32. Time- and rate-dependent alterations of the QT interval precede the onset of torsade de pointes in patients with acquired QT prolongation. Gilmour RF; Riccio ML; Locati EH; Maison-Blanche P; Coumel P; Schwartz PJ J Am Coll Cardiol; 1997 Jul; 30(1):209-17. PubMed ID: 9207644 [TBL] [Abstract][Full Text] [Related]
33. Electrocardiographic measures of repolarization heterogeneity are not predictive for Torsades de Pointes among undifferentiated patients with prolonged QTc: A case control study. Marill KA; Lopez S; Hark D; Spahr J; Shesh-Muthal K; Xue J; Rowlandson GI; Liu SW J Cardiovasc Electrophysiol; 2023 Jan; 34(1):166-176. PubMed ID: 36335640 [TBL] [Abstract][Full Text] [Related]
34. [Acquired long QT syndrome with torsade de pointes in a patient with primary hypothyroidism]. Kukla P; Szczuka K; Słowiak-Lewińska T; Bromblik A; Hajduk B; Kluczewski M; Lenard B; Przewor M Kardiol Pol; 2003 Mar; 58(3):224-6. PubMed ID: 14513098 [TBL] [Abstract][Full Text] [Related]
35. The site of origin of torsade de pointes. Birati EY; Belhassen B; Bardai A; Wilde AA; Viskin S Heart; 2011 Oct; 97(20):1650-4. PubMed ID: 21561894 [TBL] [Abstract][Full Text] [Related]
36. Sodium pentobarbital reduces transmural dispersion of repolarization and prevents torsades de Pointes in models of acquired and congenital long QT syndrome. Shimizu W; McMahon B; Antzelevitch C J Cardiovasc Electrophysiol; 1999 Feb; 10(2):154-64. PubMed ID: 10090218 [TBL] [Abstract][Full Text] [Related]
37. Mexiletine Prevents Recurrent Torsades de Pointes in Acquired Long QT Syndrome Refractory to Conventional Measures. Badri M; Patel A; Patel C; Liu G; Goldstein M; Robinson VM; Xue X; Yang L; Kowey PR; Yan GX JACC Clin Electrophysiol; 2015 Aug; 1(4):315-322. PubMed ID: 29759319 [TBL] [Abstract][Full Text] [Related]
38. Personalized, intuitive & visual QT-prolongation monitoring using patient-specific QTc threshold with pseudo-coloring and explainable AI. Alahmadi A; Davies A; Vigo M; Jay C J Electrocardiol; 2023; 81():218-223. PubMed ID: 37837739 [TBL] [Abstract][Full Text] [Related]
39. Rotors anchored by refractory islands drive torsades de pointes in an experimental model of electrical storm. Yamazaki M; Tomii N; Tsuneyama K; Takanari H; Niwa R; Honjo H; Kodama I; Arafune T; Makita N; Sakuma I; Dobrev D; Nattel S; Tsuji Y Heart Rhythm; 2022 Feb; 19(2):318-329. PubMed ID: 34678525 [TBL] [Abstract][Full Text] [Related]
40. Assessment of drug-induced proarrhythmia: The importance of study design in the rabbit left ventricular wedge model. Lu HR; Gallacher DJ; Yan GX J Pharmacol Toxicol Methods; 2016; 81():151-60. PubMed ID: 27374776 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]